NTHI · Neonc Technologies Holdings, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 |
|---|---|---|---|---|---|
| Revenue | - | - | - | $20.0K | $43.0K |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| R&D | $1.29M | - | $715.0K | $394.5K | $614.5K |
| SG&A | $488.7K | - | $903.0K | $289.7K | $137.3K |
| Total Operating Expenses | $7.06M | - | $2.20M | $1.30M | $1.59M |
| D&A | - | - | - | - | - |
| Operating Income | ($7.06M) | - | ($2.20M) | ($5.71M) | ($1.55M) |
| Interest Expense | $982.6K | - | $869.8K | $1.17M | $1.39M |
| Income Tax | - | - | - | - | - |
| Net Income | ($8.82M) | - | ($8.62M) | ($5.68M) | ($2.94M) |
| EPS - Basic | ($0.38) | - | ($0.45) | ($0.30) | ($0.18) |
| EPS - Diluted | ($0.38) | - | ($0.12) | ($0.27) | ($0.18) |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 |
|---|---|---|---|---|---|
| Cash & Equivalents | $138.6K | $58.7K | $1.51M | $125.0K | $5.44M |
| Accounts Receivable | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Accounts Payable | - | - | - | $3.07M | $4.03M |
| Current Assets | $2.10M | $1.39M | $2.96M | $1.65M | $2.22M |
| Total Assets | $3.33M | $2.82M | $4.08M | $2.99M | $8.44M |
| Current Liabilities | $16.29M | $20.04M | $15.59M | $14.48M | $8.92M |
| Long-term Debt | - | - | - | - | - |
| Total Liabilities | $16.56M | $20.33M | $15.90M | $14.80M | - |
| Stockholders' Equity | ($13.23M) | ($17.51M) | ($5.27M) | ($6.21M) | ($13.99M) |
| Retained Earnings | ($121.57M) | ($112.75M) | ($97.23M) | ($88.61M) | ($50.61M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 |
|---|---|---|---|---|---|
| Operating Cash Flow | ($6.99M) | - | - | - | $145.7K |
| Investing Cash Flow | - | - | - | - | - |
| Financing Cash Flow | $7.07M | - | - | - | ($172.6K) |
| CapEx | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 |
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | - | - | - | - | - |
| Operating margin | - | - | - | -28540.2% | -3608.1% |
| EBITDA margin | - | - | - | - | - |
| Net margin | - | - | - | -28400.9% | -6834.8% |
| Free cash flow margin | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - |
| R&D / Revenue | - | - | - | 1972.4% | 1429.1% |
| SG&A / Revenue | - | - | - | 1448.3% | 319.3% |
| Effective tax rate | - | - | - | - | - |
| Return on assets | -264.9% | - | -211.0% | -190.1% | -34.8% |
| Return on equity | 66.7% | - | 163.6% | 91.5% | 21.0% |
| Return on invested capital | - | - | - | - | - |
| Liquidity | |||||
| Current ratio | 0.13 | 0.07 | 0.19 | 0.11 | 0.25 |
| Quick ratio | 0.13 | 0.07 | 0.19 | 0.11 | 0.25 |
| Cash ratio | 0.01 | 0.00 | 0.10 | 0.01 | 0.61 |
| Leverage | |||||
| Debt / Equity | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - |
| Interest coverage | -7.2x | - | -2.5x | -4.9x | -1.1x |
| Equity multiplier | -0.25 | -0.16 | -0.78 | -0.48 | -0.60 |
| Liabilities / Assets | 4.97 | 7.20 | 3.89 | 4.95 | - |
| Efficiency | |||||
| Asset turnover | - | - | - | 0.01 | 0.01 |
| Inventory turnover | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - |
| Valuation | |||||
| P / E | - | - | - | - | - |
| P / B | - | - | - | - | - |
| P / S | - | - | - | 2969.6x | 5145.2x |
| EV / EBITDA | - | - | - | - | - |
| Growth | |||||
| Revenue growth (YoY) | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - |
| Operating income growth (YoY) | -354.8% | - | - | - | - |
| Net income growth (YoY) | -200.1% | - | - | - | - |
| EPS growth (YoY) | -111.1% | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - |
| Book value growth (YoY) | 5.4% | - | - | - | - |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing NEONC TECHNOLOGIES HOLDINGS against the 5 most active filers in the same SIC group.